turning microbe messages into medicine.

developing next-generation antimicrobials

The Mission:

Our mission is to redefine infection control, not as a war to win but as a conversation to understand.


At Marva Labs, we’re developing biologically intelligent therapies that engage the inner voice of bacteria, prompting self destruction from within. By working with microbial systems instead of against them, we aim to end antimicrobial resistance and reshape how we treat infection—through cooperation, not escalation.

Executive SummaryDownload

The Problem

Antimicrobial resistance is a growing global health threat. In 2019, approximately 1.27 million deaths were directly attributed to AMR, with nearly 5 million deaths associated with drug-resistant infections worldwide. In the United States alone, over 2.8 million AMR infections occur annually, resulting in more than 35,000 deaths.

The economic burden of AMR is substantial and escalating. In the U.S., treating just six of the most concerning AMR threats contributes to over $4.6 billion in healthcare costs each year. Globally, if current trends continue, AMR could lead to additional healthcare costs of up to $159 billion annually by 2050. ​

The Solution:

At Marva Labs, we are pioneering a novel antimicrobial platform that exploits bacterial communication systems to induce self destruction. Our flagship product, EndoVox™ (derived from endo- meaning “within” and vox meaning “voice”), utilizes death-phase extracellular vesicles (D-EVs) to deliver native microbial signals that trigger ferroptosis—an iron-dependent oxidative death pathway. By disrupting redox balance, enhancing reactive oxygen species (ROS) production, and silencing quorum sensing, EndoVox™ effectively causes pathogens to dismantle themselves from within.​

This mechanism has demonstrated potent efficacy against a broad spectrum of drug-resistant pathogens, including Gram-positive bacteria like MRSA, Gram-negative bacteria such as P. aeruginosa, and even resilient fungal biofilms like Candida auris. EndoVox™ offers a targeted, biocompatible approach to combating some of the most formidable superbugs in modern medicine.​

Traction